drugset / Trial / NCT04573855
TREATMENT WITH ANTI-SARS-COV-2 IMMUNOGLOBULIN IN PATIENTS WITH COVID-19
RandomizedParallel-groupOpen-labelTreatment
Summary
A Phase I/II clinical trial for safety and efficacy evaluation of treatment with anti-SARS-CoV-2 equine immunoglobulin (F(ab')2) in hospitalized patients with COVID-19 not requiring of invasive ventilation support.
Timeline
- Start
- 2020-12-01
- Primary completion
- 2021-02-28
- Completion
- 2021-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anti-SARS-CoV-2 immunoglobulin | Protein / enzyme biologic | — | — |